| Patents for A61K 31 - Medicinal preparations containing organic active ingredients (785,912) |
|---|
| 04/19/2001 | WO2001027123A1 Chromium-histidine complexes as nutrient supplements |
| 04/19/2001 | WO2001027119A2 Substance library containing bicyclic imidazo-5-yl-amines and/or bicyclic imidazo-3-yl-amines |
| 04/19/2001 | WO2001027118A2 Bicyclic imidazo-5-yl-amine derivatives |
| 04/19/2001 | WO2001027115A1 Pentacyclic taxane compounds |
| 04/19/2001 | WO2001027114A1 PYRROLO[2,3-d]PYRIMIDINE NUCLEOSIDE ANALOGS |
| 04/19/2001 | WO2001027113A2 PYRAZOLO `4,3-d! PYRIMIDINE DERIVATIVES |
| 04/19/2001 | WO2001027112A1 5-(2-substituted-5-heterocyclylsulphonylpyrid-3-yl)-dihydropyrazolo[4,3-d]pyrimidin-7-ones as phosphodiesterase inhibitors |
| 04/19/2001 | WO2001027111A2 Bicyclic imidazo-3-yl-amine derivatives |
| 04/19/2001 | WO2001027110A2 Bicyclic imidazo-3-yl-amine derivatives which are substituted on the sixth ring |
| 04/19/2001 | WO2001027109A2 Tert.-butyl-(7-methyl-imidazo[1,2-a]pyridine-3-yl)-amine derivatives |
| 04/19/2001 | WO2001027107A2 Heterocyclic sodium/proton exchange inhibitors and method |
| 04/19/2001 | WO2001027106A1 Substituted pyrroles as antiproliferative agents for the treatment of cancer |
| 04/19/2001 | WO2001027103A1 Fab i inhibitors |
| 04/19/2001 | WO2001027102A1 Substituted diazepanes |
| 04/19/2001 | WO2001027101A2 Anhydrous salt |
| 04/19/2001 | WO2001027099A2 Bicyclic compounds composition and method for stabilizing the same |
| 04/19/2001 | WO2001027098A2 Method for producing cox-2 inhibitors |
| 04/19/2001 | WO2001027097A1 Polymorphic b form of 3-(cyclopropylmethoxy)-4-[4-(methylsulfonyl)phenyl]-5,5-dimethyl-5h-furan-2-one |
| 04/19/2001 | WO2001027094A1 Hypertriglyceridemia remedies and antiobestics |
| 04/19/2001 | WO2001027089A1 Pyrimidine derivatives |
| 04/19/2001 | WO2001027088A1 Lpl potentiators |
| 04/19/2001 | WO2001027084A1 Beta disubstituted metalloprotease inhibitors |
| 04/19/2001 | WO2001027082A1 3-AMINOPIPERIDINE DERIVATIVES AS INTEGRIN αvβ3 ANTAGONISTS |
| 04/19/2001 | WO2001027081A1 6-position substituted indoline, production and use thereof as a medicament |
| 04/19/2001 | WO2001027072A1 Hydrated n-[3-[[2-(3,4-dimethoxyphenyl) ethyl] amino] propyl] -4-nitro benzamide hydrochloride and its use in pharmaceutical compositions |
| 04/19/2001 | WO2001027071A1 Polymorphic n-[3-[[2-(3,4-dimethoxyphenyl) ethyl] amino] propyl] -4-nitro benzamide hydrochloride |
| 04/19/2001 | WO2001027070A1 Use of carbonylamino derivatives against cns disorders |
| 04/19/2001 | WO2001027068A1 Biaryl ether derivatives useful as monoamine reuptake inhibitors |
| 04/19/2001 | WO2001026705A2 A dual adhesive transdermal drug delivery system |
| 04/19/2001 | WO2001026693A2 Manufacture of polyglutamate-therapeutic agent conjugates |
| 04/19/2001 | WO2001026691A1 Medicinal compositions for oral use |
| 04/19/2001 | WO2001026688A1 Percutaneous absorption promoters for electroporation |
| 04/19/2001 | WO2001026686A1 Skin immune function controlling agents |
| 04/19/2001 | WO2001026671A1 Methods of treatment using dual matrix-metalloproteinase-2 and matrix metalloproteinase-9 inhibitors |
| 04/19/2001 | WO2001026669A1 A nascent gold based herbal composition |
| 04/19/2001 | WO2001026668A1 Compositions with anti-prostate cancer activity |
| 04/19/2001 | WO2001026666A2 Composition for the prevention and/or treatment of circulatory disorders, comprising derivatives of l-carnitine and extracts of ginkgo biloba |
| 04/19/2001 | WO2001026663A1 Extended release formulations of erythromycin derivatives |
| 04/19/2001 | WO2001026662A1 Pharmaceutical product suitable for use immunosuppressive therapy |
| 04/19/2001 | WO2001026661A1 Compositions comprising oxophosphonate-based metalloproteinase inhibitors |
| 04/19/2001 | WO2001026660A1 Novel compositions and methods for prevention and treatment of protozoal disease |
| 04/19/2001 | WO2001026659A1 Medicament for treatment of neuropathies |
| 04/19/2001 | WO2001026658A2 Topical nasal treatment using desloratadine |
| 04/19/2001 | WO2001026657A1 Use of (r)-zacopride or a salt thereof for the manufacture of a medicament for the treatment of sleep apnea |
| 04/19/2001 | WO2001026656A2 5-membered heterocycle derivatives and use thereof as monoamine oxidase inhibitors |
| 04/19/2001 | WO2001026655A1 Metalloporphyrin treatment of neurologic disease |
| 04/19/2001 | WO2001026654A1 Fab i inhibitors |
| 04/19/2001 | WO2001026653A1 V TYPE AND/OR X TYPE sPLA2 INHIBITORS |
| 04/19/2001 | WO2001026652A1 Fab i inhibitors |
| 04/19/2001 | WO2001026651A2 Selective estrogen receptor modulators in the treatment or reduction of the risk of acquiring hypertension, cardiovascular diseases, and insulin resistance |
| 04/19/2001 | WO2001026650A2 Use of n-acyl homoserine lactones for the treatment of cardiac tachyarrhythmias, ischaemic heart disease or congestive heart failure |
| 04/19/2001 | WO2001026649A1 Use of l-carnitine and its alkanoyl derivatives as osmotic agents in solutions for medical use |
| 04/19/2001 | WO2001026648A1 Ophthalmic adhesive preparations for percutaneous absorption |
| 04/19/2001 | WO2001026647A1 Hop acids used to inhibit staphylococcus aureus |
| 04/19/2001 | WO2001026646A1 NUTRACEUTICAL PRODUCTS CONTAINING SAMe AND DIETARY SUPPLEMENTS AND METHOD OF MANUFACTURING AND USE THEREOF |
| 04/19/2001 | WO2001026645A1 Method for protecting normal cells from cytotoxicity of chemotherapeutic agents |
| 04/19/2001 | WO2001026644A2 Mediators of hedgehog signaling pathways, compositions and uses related thereto |
| 04/19/2001 | WO2001026642A2 Methods and compositions for treating neurobehavioral disorders |
| 04/19/2001 | WO2001026641A2 Morpholinol derivatives for the treatment of obesity |
| 04/19/2001 | WO2001026640A2 Treatment of osteoporosis |
| 04/19/2001 | WO2001026639A2 Pharmaceutical composition of ateglinide and another antidiabeticagent |
| 04/19/2001 | WO2001026638A2 The use of baclofen in the treatment of alcoholism |
| 04/19/2001 | WO2001026637A2 Transdermal therapeutic system for administering acetylsalicylic acid and/or salicylic acid |
| 04/19/2001 | WO2001026636A1 Superficial therapeutic system for topically applying acetylsalicylic acid, for the treatment of acne-related diseases |
| 04/19/2001 | WO2001026635A2 Bioadhesive nanoparticulate compositions having cationic surface stabilizers |
| 04/19/2001 | WO2001026629A2 Neutral-cationic lipid for nucleic acid and drug delivery |
| 04/19/2001 | WO2001026628A1 Cationic dosper virosomes |
| 04/19/2001 | WO2001026627A1 Liposome encapsulated silver salt compositions |
| 04/19/2001 | WO2001026625A2 Neutral-cationic lipid for nucleic acid and drug delivery |
| 04/19/2001 | WO2001026623A2 Treatment of fatigue, head injury and stroke |
| 04/19/2001 | WO2001026621A2 Orally distintegrating composition comprising mirtazapine |
| 04/19/2001 | WO2001026618A2 Composition, especially a cosmetic composition, containing a steroid and a liposoluble uv filter |
| 04/19/2001 | WO2001026606A2 Treatment of scar tissue using lipoic acid |
| 04/19/2001 | WO2001026605A2 Immunosuppressive composition containing il-2 inhibitor and an adenosine deaminase inhibitor |
| 04/19/2001 | WO2001026603A2 Mesoprogestins (progesterone receptor modulators) as a component of female contraceptives |
| 04/19/2001 | WO2001026481A1 Fish feed with increased nucleotide content |
| 04/19/2001 | WO2001026471A1 Pediculocidal and veterinary compositions |
| 04/19/2001 | WO2001026467A1 Methods of enhancing chemotherapy |
| 04/19/2001 | WO2001003670A8 Method for controlled production of ultrafine microparticles and nanoparticles |
| 04/19/2001 | WO2001002366A3 Substituted isoquinoline derivatives and their use as inticonvulsants |
| 04/19/2001 | WO2001001963A8 A method for the improvement of transport across adaptable semi-permeable barriers |
| 04/19/2001 | WO2000075158A3 NOVEL 6-PHENYLPURINE 9-β-D-RIBONUCLEOSIDES WITH ANTINEOPLASTIC ACTIVITY, THEIR USE FOR PREPARING PHARMACEUTICAL COMPOSITIONS AND PHARMACEUTICAL PREPARATIONS CONTAINING SUCH COMPOUNDS |
| 04/19/2001 | WO2000073274A3 Substituted phenylcyclohexane carboxylic acid amides and their use as adenosine uptake inhibitors |
| 04/19/2001 | WO2000071078A3 Composition designed for implementing an antitumoral or antiviral treatment in a mammal |
| 04/19/2001 | WO2000070086A9 Nucleic acid probe-based diagnostic assays for prokaryotic and eukaryotic organisms |
| 04/19/2001 | WO2000068380A3 Extracellular matrix and adhesion-associated proteins |
| 04/19/2001 | WO2000067762A3 Selenium-containing pro-drugs for cancer therapy |
| 04/19/2001 | WO2000067732A3 Pharmaceutical composition, containing an antimycotic, polydocanol and salicylic acid |
| 04/19/2001 | WO2000066129A3 Use of antiprogestagens in combined therapy |
| 04/19/2001 | WO2000066084A8 Aerosol formulations and devices for increasing libido in women via acute testosterone administration |
| 04/19/2001 | WO2000065073A3 Genetic sequence which codes for the flavon synthase ii enzyme and use of the same |
| 04/19/2001 | WO2000064423A3 Use of saredutant and the pharmaceutically acceptable salts thereof to produce medicaments used to treat or prevent mood disorders, adjustment disorders or mixed anxiety-depression disorders |
| 04/19/2001 | WO2000061568A3 1,4-benzothiazepine-1,1-dioxide derivatives substituted by sugar radicals, methods for the production thereof, medicaments containing these compounds and the use thereof |
| 04/19/2001 | WO2000061132A8 Compositions containing immunotoxins and agents that inhibit dendritic cell maturation for inducing immune tolerance to a graft |
| 04/19/2001 | WO2000061125A3 Osanetant in the treatment of mood disorders |
| 04/19/2001 | WO2000057873A3 Granulate with high content of l-carnitine or an alkanoyl l-carnitine |
| 04/19/2001 | WO2000057867A3 Improved cancer treatment with temozolomide |
| 04/19/2001 | WO2000047236A8 Matrices for drug delivery and methods for making and using the same |
| 04/19/2001 | WO2000046198A8 Anti-inflammatory indole derivatives |
| 04/19/2001 | WO2000045894A3 Use of pyrazole carboxamides |